A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation.

Abstract:

:Data from autologous peripheral blood progenitor cell (PBPC) transplant recipients were used for cost analysis and modelling so as to link the main intervention procedures and clinical events to resource use and costs. This cohort consisted of 64 patients from 4 to 62 years old at transplantation (mean, 36.9 years) who underwent a first transplant between August 1994 and May 1997. The main indications for transplantation were non-Hodgkin's lymphomas (47%), multiple myeloma (30%) and Hodgkin's lymphomas (15%). The course of a patient during the whole transplant procedure was modelled using a Markov chain of six states of health: (1) mobilisation and recovery of PBPC; (2) post-mobilisation phase; (3) conditioning and transplant; (4) critical haematological reconstitution; (5) non-critical haematological reconstitution; (6) death. The probability of transition between the different health states, together with the estimated costs, were the input for the Markov model. The model also managed transition probabilities depending both on the current health state and on various demographic, clinical and procedure-related covariates unique to the patient. The expected time spent in each clinical state and the expected total cost were, therefore, estimated. This analysis gave an actual total cost per transplanted patient of $26,600 (95% range: $24,700 to $43,500) while mean duration was 197 days. The expenses for in-hospital stay accounted for 80% of the costs. Both the probability of staying in the different states, and the consequent cost were dependent on the number of CD34-positive cells collected, the phase and the type of the disease, the subset of patients (either children or adults), and the post-transplant G-CSF prophylaxis. The sensitivity of the estimates to alternative assumptions was studied, and the method of comparing alternative future scenarios by the model was explored.

journal_name

Bone Marrow Transplant

authors

Barosi G,Marchetti M,Alessandrino P,Locatelli F,Casula S,Lunghi M,Cazzola M,Giraldi E,Bernasconi C

doi

10.1038/sj.bmt.1701639

subject

Has Abstract

pub_date

1999-04-01 00:00:00

pages

719-25

issue

7

eissn

0268-3369

issn

1476-5365

journal_volume

23

pub_type

杂志文章
  • The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis.

    abstract::The effect of hematopoietic growth factors on neutrophil recovery after allogeneic transplantation is well-recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of GVHD is unclear. We perform...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,meta分析

    doi:10.1038/sj.bmt.1704228

    authors: Ho VT,Mirza NQ,Junco Dd Dd,Okamura T,Przepiorka D

    更新日期:2003-10-01 00:00:00

  • Flow-cytometric immunophenotyping of acute leukaemia.

    abstract::A wide panel of commercially available monoclonal antibodies (Mo.Abs.) has substantially improved immunological distinguishing of various types of acute leukaemias (AL), whereas the flow-cytometric approach allows a more objective and sensitive cell-marker analysis; combined with high numbers of cells analyzed, it yie...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Batinić D

    更新日期:1989-12-01 00:00:00

  • New strategies in GVHD prophylaxis.

    abstract::Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a mor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702346

    authors: Kiehl MG,Shipkova M,Basara N,Blau WI,Fauser AA

    更新日期:2000-05-01 00:00:00

  • Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients.

    abstract::Results of allogeneic bone marrow transplantation (BMT) are still impaired due mainly to acute graft-versus-host disease (GVHD). Successful T cell depletion may abolish GVHD but causes increased rates of rejection and relapse. In vivo blocking of the CD25 receptor on T cells induces efficient and selective immunosuppr...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Blaise D,Olive D,Hirn M,Viens P,Lafage M,Attal M,Stoppa AM,Gabert J,Gastaut JA,Camerlo J

    更新日期:1991-08-01 00:00:00

  • The Japan Marrow Donor Program, 25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis.

    abstract::The Japan Marrow Donor Program (JMDP), established in 1991, has continued to grow in its capacity to facilitate unrelated bone marrow (BMT) and peripheral blood stem cell transplantation (PBSCT) for the past 25 years in Japan. The current donor pool is 463,465 (as of 31 December 2016) and 20,237 transplants were perfo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-017-0084-2

    authors: Saito H,Ito M,Kato S,Kodera Y,Okamoto S,Taniguchi S,Takanashi M,Kanamori H,Masaoka T,Takaku F,JMDP.

    更新日期:2018-05-01 00:00:00

  • Psychological distress of patients undergoing intensified conditioning with radioimmunotherapy prior to allogeneic stem cell transplantation.

    abstract::This is a pilot study comparing the emotional distress of patients receiving an intensified conditioning regimen (radioimmunotherapy=RIT) with patients receiving conventional conditioning for allogeneic stem cell transplantation. In total, 53 patients (18 received RIT) were given two questionnaires designed to measure...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704971

    authors: Grulke N,Bailer H,Kächele H,Bunjes D

    更新日期:2005-06-01 00:00:00

  • Secondary myelodysplastic syndrome following bone marrow transplantation: report of two cases.

    abstract::We report two cases of secondary myelodysplastic syndrome (SMDS) which followed successful treatment of a primary malignancy with high-dose chemotherapy supported by reinfusion of autologous stem cells. The SMDS was diagnosed 24 months and 40 months, respectively, following autografting. Both patients lived for 7 mont...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chan T,Juneja S,Wolf M,Januszewicz E,Cooper I

    更新日期:1994-02-01 00:00:00

  • Outcome of 67 patients with solid tumors relapsed after high-dose chemotherapy and peripheral blood stem cell transplantation.

    abstract::We retrospectively analyzed the outcome of 67 patients with breast (n=24), ovarian (n=11) or testicular cancer (n=32) treated for relapse after high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) transplantation. Treatment, survival and toxicity were analyzed. Patients with breast, ovarian or testicular...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704047

    authors: Bojko P,Akca A,Seeber S

    更新日期:2003-06-01 00:00:00

  • Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?

    abstract::Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2009.214

    authors: Freytes CO,Lazarus HM

    更新日期:2009-11-01 00:00:00

  • Mesenchymal stem cells: heading into the clinic.

    abstract::In recent years, there has been an increasing interest in non-hematopoietic pluripotent progenitor cells that are found in the bone marrow. Mesenchymal stem cells (MSCs) are the first non-hematopoietic progenitors to be isolated from the bone marrow and extensively characterized. In addition to their ability to suppor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1702791

    authors: Koç ON,Lazarus HM

    更新日期:2001-02-01 00:00:00

  • Cataracts in patients receiving stem cell transplantation after conditioning with total body irradiation.

    abstract::One hundred and ninety-three patients with hematological malignancies and a follow-up > or =1 year, treated with stem cell transplantation (45 autologous, 99 allogeneic T cell-depleted matched, 49 allogeneic T cell-depleted mismatched) from July 1985 to May 1998, were considered evaluable for the development of catara...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703400

    authors: Aristei C,Alessandro M,Santucci A,Aversa F,Tabillo A,Carotti A,Latini RA,Cagini C,Latini P

    更新日期:2002-03-01 00:00:00

  • Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.

    abstract::Between December 1983 and November 1985 we treated 39 patients with chronic myeloid leukaemia by chemoradiotherapy and transplantation from HLA-identical sibling donors using bone marrow that had been depleted of T cells ex vivo with the rat monoclonal antibody Campath-1. Twenty-eight of the patients were in the chron...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Apperley JF,Jones L,Hale G,Waldmann H,Hows J,Rombos Y,Tsatalas C,Marcus RE,Goolden AW,Gordon-Smith EC

    更新日期:1986-05-01 00:00:00

  • Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. A pilot study of the non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).

    abstract::Twenty successive adult patients with lymphoblastic lymphoma entered a study of sequential chemotherapy consisting of an intensive LSA2-L2-type protocol to induce first complete remission. Twelve patients in first CR (median age 22 years, range 15-43), after receiving a conditioning regimen consisting of cyclophospham...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Santini G,Coser P,Chisesi T,Porcellini A,Sertoli R,Contu A,Congiu AM,Manna A,Rossi E,Scarpati D

    更新日期:1989-07-01 00:00:00

  • The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.

    abstract::Results in 164 patients who underwent allogeneic marrow transplantation following busulfan and cyclophosphamide over a 15 year period were analyzed. Age (median 37, range 14-66 years) did not significantly affect the incidence of graft-versus-host disease (GVHD), but patients who received methotrexate with cyclosporin...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702689

    authors: Copelan EA,Penza SL,Theil KS,Elder PJ,Bechtel TP,Tighe MB,Ezzone SA,Scholl MD,Belt PS,Young DC,Avalos BR

    更新日期:2000-11-01 00:00:00

  • Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion.

    abstract::We describe seven patients who developed symptoms including severe headache, circumoral paresthesia, and facial flushing during high-dose carmustine (BCNU) infusion as part of the preparative regimen for autologous peripheral blood stem cell (PBSC) transplantation for metastatic breast cancer. Five patients responded ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700743

    authors: Woo MH,Ippoliti C,Bruton J,Mehra R,Champlin R,Przepiorka D

    更新日期:1997-04-01 00:00:00

  • Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries.

    abstract::Hemorrhagic cystitis (HC) is a common and sometimes life-threatening complication of hemopoietic cell transplantation (HCT) occurring in 7-52% of transplant recipients. In this setting it is usually either related to the use of cyclophosphamide or to a viral infection (BK, JC viruses and adenovirus type 11). Treatment...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703954

    authors: Giné E,Rovira M,Real I,Burrel M,Montaña J,Carreras E,Montserrat E

    更新日期:2003-05-01 00:00:00

  • Collection of peripheral blood progenitor cells (PBPC) based on a rising WBC and platelet count significantly increases the number of CD34+ cells.

    abstract::The kinetics of mobilization and optimal timing of peripheral blood progenitor cell (PBPC) collection were evaluated in 190 patients with multiple myeloma undergoing stem cell harvest after mobilization with cyclophosphamide, prednisone and G-CSF. There was a strong correlation between the WBC count and the number of ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.bmt.1701817

    authors: Krieger MS,Schiller G,Berenson JR,Stewart K,Noga SJ,Ballester O,Tarantolo S,Stiff P,Kuhn D,Scherzo E,Sing A,Jacobs C,White JM,DiPersio J

    更新日期:1999-07-01 00:00:00

  • Human-ovine xenogenic transplantation of stem cells in utero.

    abstract::The preimmune status of the early gestational age fetus provides a permissive environment that bypasses the immunological barrier and permits the engraftment and expression of hemopoietic stem cells (HSC). We used in utero approach to establish long term (greater than 2 years) engraftment and expression of human fetal...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zanjani ED,Pallavacini MG,Ascensao JL,Flake AW,Harrison MR,Tavassoli M

    更新日期:1992-01-01 00:00:00

  • Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA).

    abstract::The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.139

    authors: Isfan F,Kanold J,Merlin E,Contet A,Sirvent N,Rochette E,Poiree M,Terral D,Carla-Malpuech H,Reynaud R,Pereira B,Chastagner P,Simeoni MC,Auquier P,Michel G,Deméocq F

    更新日期:2012-05-01 00:00:00

  • Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases.

    abstract::Persistent thrombocytopenia and thrombotic complications are commonly observed in bone marrow transplant (BMT) patients. We describe two incidents following BMT in which heparin may have played a contributory role. One patient developed subclavian venous thrombosis following autologous BMT in spite of the severe throm...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tezcan AZ,Tezcan H,Gastineau DA,Armitage JO,Haire WD

    更新日期:1994-09-01 00:00:00

  • Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

    abstract::Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripher...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.74

    authors: Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

    更新日期:2015-07-01 00:00:00

  • Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.

    abstract::This retrospective study was conducted to determine whether the total number of nucleated cells (TNC)/kg collected at marrow harvest was associated with outcome in 151 patients with acute myelogenous leukemia (AML) who received an autologous purged (n = 67) or non-purged (n = 84) marrow transplant. At the time of tran...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Demirer T,Gooley T,Buckner CD,Petersen FB,Lilleby K,Rowley S,Sanders J,Storb R,Appelbaum FR,Bensinger WI

    更新日期:1995-06-01 00:00:00

  • Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.

    abstract::Rapid, specific and sensitive methods are essential for early detection of CMV infection in patients after marrow transplantation. Thus, in a prospective study, PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture were used and compared in 20 consecutive marrow transplant recipients for early diagnosis...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Hebart H,Müller C,Löffler J,Jahn G,Einsele H

    更新日期:1996-05-01 00:00:00

  • Ruxolitinib treatment for GvHD in patients with myelofibrosis.

    abstract::Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibros...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.256

    authors: Mori Y,Ikeda K,Inomata T,Yoshimoto G,Fujii N,Ago H,Teshima T

    更新日期:2016-12-01 00:00:00

  • A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.

    abstract::We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifostine was given at a dose of 1000 mg/day of conditioning and was well tolerated if attention was given to seru...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1704521

    authors: Hwang WY,Koh LP,Ng HJ,Tan PH,Chuah CT,Fook SC,Chow H,Tan KW,Wong C,Tan CH,Goh YT

    更新日期:2004-07-01 00:00:00

  • In vitro and in vivo depletion of T cells.

    abstract::Transplant related mortality and relapse after bmt have a negative influence on the outcome of patients transplanted for acute leukaemia in first remission. Transplant related mortality includes graft-versus-host disease, infections and graft failure. To prevent gvhd and associated infections without increased graft r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Arnold R,Bunjes D,Wiesneth M,Hertenstein B,Theobald M,Heimpel H,Hale G,Waldmann H

    更新日期:1993-01-01 00:00:00

  • Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest.

    abstract::The aim of this study was to compare anxiety, pain and discomfort of cancer patients submitted to either peripheral blood progenitor cell collection (PBPCC) or bone marrow harvest (BMH). Patients, randomized (7/1993-2/1994), in view of autograft, to receive the first procedure or the second one, completed self-adminis...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Auquier P,Macquart-Moulin G,Moatti JP,Blache JL,Novakovitch G,Blaise D,Faucher C,Viens P,Maraninchi D

    更新日期:1995-10-01 00:00:00

  • Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.

    abstract::Hematopoietic growth factors like G-CSF or GM-CSF have been shown to shorten the period of severe neutropenia after HD chemotherapy and autologous BMT, and are now widely used to mobilize hemopoietic stem cells into peripheral blood. In order to evaluate the possibility of delaying G-CSF administration after transplan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Faucher C,Le Corroller AG,Chabannon C,Novakovitch G,Manonni P,Moatti JP,Nouyrigat P,Maraninchi D,Blaise D

    更新日期:1996-04-01 00:00:00

  • HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies.

    abstract::HLA-haploidentical hematopoietic SCT (HSCT) provides an opportunity for almost all patients who lack HLA-matched sibling donors. The donor availability can be increased by including the collateral related donors (CRDs). We compared clinical outcomes of patients with hematological malignancies, who underwent haploident...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.223

    authors: Zhang YY,Liu DH,Liu KY,Xu LP,Chen H,Han W,Wang Y,Huang XJ

    更新日期:2014-04-01 00:00:00

  • Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation.

    abstract::Short stature is characteristic of Hurler syndrome, or mucopolysaccharidosis type IH (MPS IH). Hematopoietic stem cell transplantation (HSCT) is used to treat children with MPS IH. While HSCT corrects some of the metabolic features of MPS IH, its effects on growth are not well delineated. We investigated growth in pat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.20

    authors: Polgreen LE,Tolar J,Plog M,Himes JH,Orchard PJ,Whitley CB,Miller BS,Petryk A

    更新日期:2008-06-01 00:00:00